A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL)

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Pegaspargase (Primary) ; Sugemalimab (Primary)
Indications Extranodal NK-T-cell lymphoma
Focus Therapeutic Use
Sponsors CStone Pharmaceuticals

Most Recent Events

01 Jan 2025 Planned initiation date changed from 1 Nov 2024 to 1 Jun 2025.
08 Aug 2024 Planned initiation date changed from 1 Jul 2024 to 1 Nov 2024.
07 Nov 2023 Planned End Date changed from 1 Oct 2027 to 1 Nov 2028.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight